ERBB2 and breast carcinoma: Currently, there is an ongoing study, ATOP phase II clinical trial (NCT03587740), investigating the potential of replacing the use of trastuzumab plus chemotherapy with T-DM1 as a single first line treatment in patients with early HER2-positive breast cancer [70].